论文部分内容阅读
为了探讨趋化因子受体CXCR4、CCR1、CCR2与多发性骨髓瘤(multiple myeloma,MM)疗效的关系,采用流式细胞术检测48例初发MM病人骨髓中MM细胞表面CXCR4、CCR1、CCR2的表达情况。患者分为2组,表达至少1个趋化因子受体的归为趋化因子受体表达阳性组(Ⅰ组),不表达趋化因子受体的归为趋化因子受体表达阴性组(Ⅱ组)。经过化疗3、6个月后分别评价和比较各组的疗效。结果显示:经过化疗3个月后,Ⅰ组患者(34例,中途失访3例)化疗有效率80.6%(25/31),Ⅱ组患者(14例)化疗有效率50%(7/14);经过化疗6个月后,Ⅰ组患者化疗有效率83.9%(26/31),Ⅱ组患者化疗有效率50%(7/14),无论经过化疗3个月还是经过化疗6个月,2组患者的有效率的差异均有统计学意义(p<0.05)。结论:CXCR4、CCR1、CCR2可以作为预测MM疗效的指标。
To investigate the relationship between chemokine receptor CXCR4, CCR1, CCR2 and multiple myeloma (MM), the expression of CXCR4, CCR1 and CCR2 on the surface of MM cells in 48 patients with primary MM was detected by flow cytometry Express the situation. Patients were divided into two groups, those expressing at least one chemokine receptor were classified as positive for chemokine receptor expression (group I), those that did not express chemokine receptors were classified as negative for chemokine receptor expression Group Ⅱ). After 3 and 6 months of chemotherapy, the efficacy of each group was evaluated and compared. The results showed that after 3 months of chemotherapy, the effective rate of chemotherapy was 80.6% (25/31) in group Ⅰ (34 cases, 3 cases lost at midway), and 50% (Ⅱ) in group Ⅱ (14/14) ). After 6 months of chemotherapy, the effective rate of chemotherapy in group Ⅰ was 83.9% (26/31) and in group Ⅱ was 50% (7/14). Chemotherapy 3 months or 6 months after chemotherapy, The differences in the effective rates between the two groups were statistically significant (p <0.05). Conclusion: CXCR4, CCR1, CCR2 can be used as predictors of MM efficacy.